<DOC>
	<DOCNO>NCT01427244</DOCNO>
	<brief_summary>This phase II open-label study activity safety trastuzumab patient vulvar Paget 's disease overexpression HER2 biopsy .</brief_summary>
	<brief_title>Evaluation Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget 's Disease</brief_title>
	<detailed_description>The primary objective estimate anti-tumor activity trastuzumab evaluate response trastuzumab therapy patient recurrent persistent vulvar Paget 's disease demonstrate HER2/neu overexpression immunohistochemistry and/ FISH ( ( fluorescence situ hybridization ) . The secondary objective : - To evaluate quality life , base severity patient ' vulvar itch 4-point verbal rating scale 0 3 ( 0=no itching , 1=mild itching/ bothersome , 2=moderate itching/ troublesome , 3=severe itching/ extremely troublesome ) well severity patient ' vulvar pain numeric pain scale 0-10 ( 0=no pain , 1-3=mild pain , 4-6=moderate pain , 7-10=severe pain ) . - To assess frequency severity observe adverse effect - To assess frequency/ incidence HER2 Paget 's disease vulva</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>recurrent persistent vulvar Paget 's disease overexpression HER2 immunohistochemistry fluorescence situ hybridization ( FISH ) Biopsy histologic confirmation Measurable disease Karnofsky score 50100 recovered effect recent surgery , radiotherapy , chemotherapy free active infection require antibiotic adequate bone marrow function , renal function , hepatic function , cardiac function , WOCBPneg.serum pregnancy , meet requirement section 7.0 measurable disease tumor HER2 positive immunohistochemistry FISH prior therapy antiHER2 monoclonal antibody preparation Karnofsky score 040 invasive malignancy , exception nonmelanoma skin cancer Patients require supplemental oxygen unstable medical condition opinion treat physician place unacceptably increase risk trastuzumab therapy Patients active unstable cardiac disease , myocardial infarction within 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HER2+</keyword>
	<keyword>Histologic confirmation</keyword>
	<keyword>measurable disease</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>HER2 overexpression</keyword>
	<keyword>persistent vulvar Paget 's disease</keyword>
	<keyword>recurrent vulvar Paget 's disease</keyword>
</DOC>